A frequent quantification of drugs concentrations in plasma of patients subject to chemotherapy is seldom performed, mostly because the standard methods (Gas or Liquid Chromatography coupled with Mass Spectroscopy) are expensive and time consuming. In this paper we report the approach pursued in one of the research units of the EU project RAMAN4CLINICS to tackle the problem of a low cost, time adherent quantification of drugs used for oncological patients using a Surface Enhanced Raman Scattering (SERS) spectroscopy. More specifically, the issues concerning the repeatability of the nanostructured substrates will be presented and some promising results to increase the selectivity of the measures toward specific drugs will be discussed, with examples concerning one cytotoxic agent, Irinotecan and one kinase inhibitor, Sunitinib.
INTRODUCTION
Chemotherapeutic drugs are expensive, have rather heavy side effects on patients, and are usually effective in a very narrow therapeutic window of plasmatic concentrations. All these factors point to the opportunity to optimize their use, adjusting in real time the dosage of the drugs administered to the patients in what is called Therapeutic Drug Monitoring (TDM). Unfortunately, the golden standard for the quantification of drugs in the course of chemotherapeutic treatments is Mass Spectroscopy coupled with High Performance Liquid Chromatography (HPLC-MS), which is both time consuming and expensive. Consequently, TDM is seldom performed on oncological patients and the administration of the drugs is grossly adjusted on the base of the side effects as reported by the patients or as inferred from the routine blood analysis. Simple, rapid and low-cost methods for chemotherapeutic drugs quantification are thus needed to effectively implement TDM. In this contribution we outline an approach that we are pursuing to reach this goal by using a combination of Raman spectroscopy, nanotechnology and chemometrics. Raman spectroscopy in particular has long attracted the interest of the medical community as an analytical tool and it is at the heart of a European initiative called RAMAN4CLINICS, aimed at introducing Raman spectroscopy in clinical practice. One of the activities of RAMAN4CLINICS is specifically devoted to TDM, and the approach used constitutes the backbone of this contribution. When molecules are absorbed on nanostructured metal surfaces, their Raman spectral signature is highly enhanced: this effect is known as Surface Enhanced Raman Scattering (SERS), where the enhancement is up to billions of time (with respect to the spectrum of the same analyte with the same concentration but without adsorption on the nanostructured metal surface). The strong SERS enhancement can be exploited to obtain information from chemotherapeutic drugs in concentration of interest for the oncological patients, typically from nanomolar to micromolar. SERS approaches for drug quantification have been previously tried, also using a separation step different than HPCL (e.g. TLC) before SERS analysis [1] . Once the SERS spectra are obtained, several chemometric techniques can be applied to obtain calibration curves/models capable of establishing appropriate relationships between instrumental responses and the concentration of the drugs of interest in blood/plasma/serum of the patients, which is the ultimate goal. 
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Preliminary S surrogate ma similar to tho during such t acquiring the minus one int drug concent necessary, th biofluids such of the matrix. 600  700  800  900  1000  1100  1200  1300  1400  1500  1600  1700 Raman Shift (cm -1) Multiv to calibration (PLSR) serum/plasma components may contribute to the measured intensity at a specific Raman shift, making often impossible to differentiate an analyte-specific signal from an interfering one when looking only at one point of a data spectrum. An alternative is a multivariate calibration, using multiple responses simultaneously (e.g., the response at a range of Raman shifts, or over the entire range collected, to calculate concentrations), which may overcome most of the limitations of univariate calibration. In figure 5 we report promising preliminary results of Methotrexate (MTX) quantification in diluted human serum with SERS substrate and chemometric analysis: multivariate calibration models built using partial least-squares regression (PLSR) were compared with univariate calibration. The PLS model outperformed the univariate model. 
CONCLUSIONS
In this work, we present solid SERS substrates of Au and Ag NPs, developed with a simple dip-coating method, able to quantify anticancer drugs in a model PBS solution and in a complex matrix, such as diluted human serum, as well if the SERS technique is combined with multivariate calibration. However, the substrates sensitivity its still too low to detect some anticancer agent, such as Irinotecan, in biofluids in therapeutic plasmatic values and moreover, the observed prediction error obtained with multivariate calibration it is still too high if compared with the value provided by established reference methods. Thus, an increase in selectivity and sensitivity of the SERS substrates is necessary. For this reason, we present preliminary results of substrates functionalization using the host-guest supramolecular approach, which increase the substrates sensitivity, at least in a PBS solution, of Irinotecan concentration detection of 2 orders of magnitude. Moreover, we show the advantages of multivariate regression methods with respect to univariate calibration, in the case of MTX.
Overall, this contribution reports the logical procedure used in one of the approaches of the Working Group 1 (Therapeutic monitoring of antitumoral drugs and antibiotic in body fluids) of the EU COST (European Cooperation in Science and Technology) action RAMAN4CLINICS.
